Skip to main content Back to Top
Advertisement

4/12/2021

Thiamine Injection

Products Affected - Description

    • Thiamine injection, Fresenius Kabi, 100 mg/mL, 2 mL vial, 25 count, NDC 63323-0013-02
    • Thiamine injection, Hikma, 100 mg/mL, 2 mL vial, 25 count, NDC 00641-6228-25
    • Thiamine injection, Mylan Institutional, 100 mg/mL, 2 mL vial, 25 count, NDC 67457-0196-02
    • Thiamine injection, Sagent, 100 mg/mL, 2 mL vial, 25 count, NDC 25021-0500-02

Reason for the Shortage

    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional did not provide a reason for the shortage.
    • Sagent has thiamine injection on shortage due to manufacturing delays.

Estimated Resupply Dates

    • Fresenius Kabi has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of late-April 2021.
    • Hikma has thiamine 100 mg/mL 2 mL vials on allocation.
    • Mylan Institutional has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of late-June to early-July 2021.
    • Sagent has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of April 2021.

Updated

Updated April 12, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 13, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.